Home' Australian Pharmacist : Australian Pharmacist September 2015 Contents Australian Pharmacist September 2015 I © Pharmaceutical Society of Australia Ltd.
AndroForte 5 (testosterone) is Australia’s
only TGA approved testosterone
cream for the treatment for confirmed
androgen deficiency in men according
to Lawley Pharmaceuticals. It was PBS
listed in August. AndroForte 5 is a
50mg/mL testosterone cream supplied
in a 50mL tube with a syringe measuring
device. In a clinical trial, AndroForte
5 demonstrated bio-equivalence
with the market leading transdermal
testosterone gel, Testogel.
Michael Buckley, pharmacist and
Medical Director of Perth based Lawley
Pharmaceuticals said: ‘The hormone
testosterone plays vital role in the
quality of life of men with confirmed
androgen deficiency. AndroForte 5 now
provides doctors and patients with a
more highly concentrated, alcohol-free
testosterone option for topical
Full product information can be
downloaded at: www.lawleypharm.com.au
1. schedule of pharmaceutical benefits, www.pbs.gov.au
Preservative-free relief for itchy
preservative-free relief for itchy, allergic
eyes using the unique COMOD® multi-
dose application system which delivers
at least 300 sterile drops from every
bottle, and protects the solution from
contaminated ambient air.
CROMO-FReSH is both preservative-
free and phosphate-free, and is the
only preservative-free treatment for
allergic eyes in a handy multi-dose
bottle – ideal for treating allergies
on-the-go. Without preservatives,
CROMO-FReSH also reduces the
potential for further irritation in eyes
already suffering an allergic reaction.
CROMO-FReSH eye drops
(sodium cromoglycate 2% w/v,
10mL) are for the treatment and
prevention of allergic eye conditions
such as allergic conjunctivitis and
vernal keratoconjunctivitis. Using
CROMO FReSH for about a week before
the expected allergy season may help
reduce the symptoms associated with
CROMO-FReSH is suitable for use
by adults and children, and is only
available from pharmacies ($15.99
RRP). For more information contact AFT
Pharmaceuticals on 1800 2387 4276.
On 1 August Pomalyst (pomalidomide)
was listed on the Pharmaceutical
Benefits Scheme (PBS) in combination
with dexamethasone, for the treatment
of patients with relapsed and refractory
multiple myeloma who have failed prior
treatment regimens with lenalidomide
Treatment options available to patients
with relapsed and refractory multiple
myeloma who have failed bortezomib
and lenalidomide are extremely limited.
Those whose disease has progressed
after standard treatments often
experience significant disease-related
co-morbidities, adverse events and poor
quality of life.2 According to Celgene the
announcement of Pomalyst’s PBS listing
provides a new treatment option and
renewed hope of better outcomes for
A capsule taken once a day, Pomalyst
is the first next-generation myeloma
treatment to offer prolonged survival
in combination with dexamethasone
in this group of relapsed and refractory
Pomalyst plus dexamethasone has been
shown to increase overall survival to
12.7 months (vs 8.1 months with high-
dose dexamethasone)1 and maintain
quality of life as measured by global
health status markers, which include
physical and emotional functioning,
fatigue and pain.
Pomalyst also offers
patients the convenience of an oral
once-daily dosage regime3 and has a
manageable safety profile with the most
common grade 3 or 4 adverse event
1. san miguel J, et al. lancet oncology, 2013;14:1055–66 .
2. dimopoulos m, et al. leukemia, 2014.
3. pomalyst product information. 30 apr 2015.
4. wang t, et al. leukemia & lymphoma, 2014;55(2):337–41 .
5. donk n, et al. expert opinion on pharmacotherapy,
6. Chanan-Khan a, et al. blood Cancer Journal, 2013;1–8 .
7. song K, et al. haematologica, 2015;100:e63-67.
Links Archive Australian Pharmacist August 2015 Australian Pharmacist October 2015 Navigation Previous Page Next Page